<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107192</article-id><article-id pub-id-type="publisher-id">ACM-36441</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_75778524.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  低表达miR-210-3p调控大鼠垂体瘤GH3与MMQ细胞株增殖与迁移
  The Low Expression of miR-210-3p Regulates the Proliferation and Migration of GH3 and MMQ Cell Lines in Rat Pituitary Adenoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>成浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谭</surname><given-names>维康</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>亚楠</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>建鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>维成</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>滨州医学院免疫学实验室，山东 烟台</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院神经外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1260</fpage><lpage>1268</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨低表达miR-210-3p对大鼠垂体瘤GH3和MMQ细胞株的增殖与迁移的作用。方法：将培养好的大鼠垂体瘤MMQ与GH3细胞株随机分为低表达miR-210-3p组和阴性对照组，分别转染miR-210-3p inhibitor和miR-210-3p NC，荧光定量PCR检测实验组与对照组的miR-210-3p的表达；转染后24 h、48 h、72 h分别进行CCK8检测增殖能力；用Transwell来检测大鼠垂体瘤细胞的迁移能力；用Western- boltting技术分别检测低表达miR-210-3p组和阴性对照组的FGFRL-1的蛋白表达；用双荧光素酶实验验证miR-210-3p的靶基因。结果：转染低表达病毒后MMQ与GH3垂体瘤细胞株的细胞增殖能力下降较阴性对照组比较差异，P &lt; 0.05，有统计学意义；低表达miR-210-3p组MMQ与GH3垂体瘤细胞系与阴性对照组相比细胞迁移能力下降，P &lt; 0.05，有统计学意义；转染低表达病毒组的细胞株与对照组相比，靶基因蛋白表达有差异，P &lt; 0.05；miR-210-3p可与FGFRL-1 mRNA的3’-UTR结合，FGFRL-1为miR-210-3p的靶基因。结论：miR-210-3p低表达抑制大鼠垂体瘤细胞的增殖与迁移。
    Objective: To investigate the role of miR-210-3p in regulating the proliferation and migration of GH3 and MMQ cell lines. Methods: The cultured rat pituitary adenoma MMQ and GH3 cell lines were randomly divided into the low-expression miR-210-3p group and the negative control group. The expression of miR-210-3p was transfected with miR-210-3p inhibitor and miR-210-3p NC, respectively. After transfection, proliferation capacity of CCK8 was detected at 24 h, 48 h and 72 h, respectively. Transwell was used to detect the migration ability of pituitary tumor cells in rats. The protein expression of fgfrl-1 in the low miR-210-3p group and the negative control group was detected by western-boltting technique. The target genes of miR-210-3p were verified by double luciferase assay. Results: After transfection with the low expression virus, the decreased cell proliferation of the pituitary adenoma cell lines MMQ and GH3 was significantly lower than that of the negative control group (P &lt; 0.05). Compared with the negative control group, MMQ and GH3 pituitary adenoma cell lines in the low-expression miR-210-3p group showed decreased cell migration, P &lt; 0.05, which was statistically significant. Compared with the control group, the expression of target gene protein was different in the transfected low-expression virus group (P &lt; 0.05). miR-210-3p can bind to 3'-utr of FGFRL-1 mRNA, and FGFRL-1 is the target gene of miR-210-3p. Conclusion: The low expression of miR-210-3p inhibited the proliferation and migration of MMQ and cells. 
  
 
</p></abstract><kwd-group><kwd>miR-210-3p，FGFRL-1，大鼠垂体瘤细胞株，增殖，迁移, miR-210-3p</kwd><kwd> FGFRL-1</kwd><kwd> Rat Pituitary Adenoma Cell Line</kwd><kwd> Proferation</kwd><kwd> Migration</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>低表达miR-210-3p调控大鼠垂体瘤GH3与MMQ细胞株增殖与迁移</title><p>王成浩<sup>1*</sup>，谭维康<sup>1</sup>，蒋亚楠<sup>2</sup>，王建鹏<sup>1</sup>，姚维成<sup>1#</sup></p><p><sup>1</sup>青岛大学附属医院神经外科，山东 青岛</p><p><sup>2</sup>滨州医学院免疫学实验室，山东 烟台</p><disp-formula id="hanspub.36441-formula16"><graphic xlink:href="//html.hanspub.org/file/18-1571396x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年6月5日；录用日期：2020年7月1日；发布日期：2020年7月8日</p><disp-formula id="hanspub.36441-formula17"><graphic xlink:href="//html.hanspub.org/file/18-1571396x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨低表达miR-210-3p对大鼠垂体瘤GH3和MMQ细胞株的增殖与迁移的作用。方法：将培养好的大鼠垂体瘤MMQ与GH3细胞株随机分为低表达miR-210-3p组和阴性对照组，分别转染miR-210-3p inhibitor和miR-210-3p NC，荧光定量PCR检测实验组与对照组的miR-210-3p的表达；转染后24 h、48 h、72 h分别进行CCK8检测增殖能力；用Transwell来检测大鼠垂体瘤细胞的迁移能力；用Western- boltting技术分别检测低表达miR-210-3p组和阴性对照组的FGFRL-1的蛋白表达；用双荧光素酶实验验证miR-210-3p的靶基因。结果：转染低表达病毒后MMQ与GH3垂体瘤细胞株的细胞增殖能力下降较阴性对照组比较差异，P &lt; 0.05，有统计学意义；低表达miR-210-3p组MMQ与GH3垂体瘤细胞系与阴性对照组相比细胞迁移能力下降，P &lt; 0.05，有统计学意义；转染低表达病毒组的细胞株与对照组相比，靶基因蛋白表达有差异，P &lt; 0.05；miR-210-3p可与FGFRL-1 mRNA的3’-UTR结合，FGFRL-1为miR-210-3p的靶基因。结论：miR-210-3p低表达抑制大鼠垂体瘤细胞的增殖与迁移。</p><p>关键词 :miR-210-3p，FGFRL-1，大鼠垂体瘤细胞株，增殖，迁移</p><disp-formula id="hanspub.36441-formula18"><graphic xlink:href="//html.hanspub.org/file/18-1571396x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/18-1571396x8_hanspub.png" /> <img src="//html.hanspub.org/file/18-1571396x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>垂体腺瘤是颅内常见的中枢神经系统肿瘤 [<xref ref-type="bibr" rid="hanspub.36441-ref1">1</xref>]，虽然垂体瘤是良性肿瘤，但其常呈侵袭性生长，常累及周围重要的结构，导致内分泌异常 [<xref ref-type="bibr" rid="hanspub.36441-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36441-ref3">3</xref>]、视力障碍以及颅内压增高等各种并发症 [<xref ref-type="bibr" rid="hanspub.36441-ref4">4</xref>]，目前仍缺乏针对侵袭性垂体腺瘤的有效药物 [<xref ref-type="bibr" rid="hanspub.36441-ref5">5</xref>]。近年来，随着人们对分子生物学的研究进展，我们发现微小RNA (后简称miR)在人体的疾病发展与转归中起着不可或缺的作用，微小RNA是一类由17~27个核苷酸组成的内源性非编码小RNA [<xref ref-type="bibr" rid="hanspub.36441-ref6">6</xref>]，许多真核微生物都有表达，最早在线虫体内发现。MiRNAs通过结合目的基因 mRNA 3′非编码区，使目的基因mRNA降解或抑制mRNA翻译 [<xref ref-type="bibr" rid="hanspub.36441-ref7">7</xref>]。miR-210-3p基因位于第11号染色体短臂的末端(11p15.5)，目前发现的miR-210靶基因已达50余个 [<xref ref-type="bibr" rid="hanspub.36441-ref8">8</xref>]。miR-210通过调控这些基因的表达，广泛参与体内各种生理及病理代谢过程(如多种成体干细胞的发育、胚胎的发育、细胞生长和凋亡 [<xref ref-type="bibr" rid="hanspub.36441-ref8">8</xref>]、细胞分化、血管生成 [<xref ref-type="bibr" rid="hanspub.36441-ref9">9</xref>]、免疫系统的调控及肿瘤的发生、发展等) [<xref ref-type="bibr" rid="hanspub.36441-ref10">10</xref>]。据报道，miR-210-3p与许多肿瘤的表达有异常表达，如胰腺癌、乳腺癌以及肾透明细胞癌。但是在垂体腺瘤中的表达还未见报道，miR-210在垂体腺瘤的作用机制还有待阐明 [<xref ref-type="bibr" rid="hanspub.36441-ref17">17</xref>]。我们通过TargetScan 7.2预测的miR-210-3p的靶基因为FGFRL-1，FGFRL-1是一种单通道I型膜蛋白，属于FGF受体家族, 它们调节大多数细胞类型 [<xref ref-type="bibr" rid="hanspub.36441-ref11">11</xref>] 的生长、凋亡、分化和迁移。FGFRL1对细胞增殖有负作用 [<xref ref-type="bibr" rid="hanspub.36441-ref12">12</xref>]。2018年9月至2019年12月我们拟在分子生物学角度，探讨低表达miR-210-3p对大鼠垂体瘤MMQ与GH3细胞的增殖与迁移作用与机制。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 细胞、特殊试剂来源</title><p>大鼠垂体瘤细胞系MMQ与GH3购于ATCC细胞库。特殊试剂和实验材料：FGFRL1一抗(Abcam) ab95940；CCK-8试剂盒(东仁化学)；Lipofectamine3000 (Thermo)；Transwell (Millipore)；荧光定量PCR试剂盒(Takara)；反转录试剂盒(Takara)；双荧光素酶试剂盒(Promega) Dual-Luciferase Reporter Assay System。</p></sec><sec id="s4_2"><title>2.2. 细胞培养、转染与分组</title><p>将MMQ与GH3细胞株于DMEM+10%FBS培养基中培养，培养环境温度为37℃，培养二氧化碳浓度为5%。当细胞密度大于30%时，将细胞随机分为阴性对照组与低表达组。使用Lipofectamine3000分别转染miR-210-3p inhibitor和miR-210-3p NC。分别于转染的24 h、48 h收集细胞(引物序列见表1)。采用qPCR技术检测MMQ与GH3细胞中的miR-210-3p表达，低表达组的miR-210-3p表达低于阴性对照组，表面转染成功。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Primer sequenc</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Gene</th><th align="center" valign="middle" >Upstream primer</th><th align="center" valign="middle" >Downstream primer</th></tr></thead><tr><td align="center" valign="middle" >miR-210-3p</td><td align="center" valign="middle" >5'-TGCGGCTGTGCGTGTGACAGCGG-3'</td><td align="center" valign="middle" >5'-CCAGTGCAGGGTCCGAGGT-3'</td></tr><tr><td align="center" valign="middle" >U6</td><td align="center" valign="middle" >5'-CTCGCTTCGGCAGCACA-3'</td><td align="center" valign="middle" >5'-AACGCTTCACGAATTTGCGT-3'</td></tr><tr><td align="center" valign="middle" >GAPDH</td><td align="center" valign="middle" >5'-AAGAAGGTGGTGAAGCAGGC-3'</td><td align="center" valign="middle" >5'-TCCACCACCCTGTTGCTGTA-3'</td></tr></tbody></table></table-wrap><p>表1. 引物序列</p><p>(60℃退火30 s)。</p></sec><sec id="s4_3"><title>2.3. MMQ与GH3细胞增殖测定</title><p>接种细胞于96孔板内(分别于接种后24 h、48 h、72 h进行CCK-8检测)，每组细胞设置3个复孔；进行CCK-8检测前，向待测孔内加入10 μL CCK-8检测液，避光放入37℃培养箱孵育2 h后将96孔板放入酶标仪检测。</p></sec><sec id="s4_4"><title>2.4. MMQ与GH3细胞迁移检测</title><p>将低表达miR-210-3p组和阴性对照的细胞在转染12 h后，离心，去上清，以500 μL无血清培养基重悬细胞，并进行细胞计数；然后将各组细胞加入Transwell小室内，每室加入2 &#215; 10<sup>5</sup>个细胞。小室置于24孔板中，板内下室加入600 μL含血清完全培养基，继续培养48 h后将24孔培养皿内的细胞悬液充分轻柔吹打均匀，用等体积PBS在清洗相应的孔，与悬液合并加入流式管，上机检测管内细胞数目。</p></sec><sec id="s4_5"><title>2.5. MMQ与GH3细胞中的FGFRL-1蛋白表达检测</title><p>采用Western-blotting技术，在转染48 h后收集细胞，根据试剂盒说明书提取总蛋白并变性，完成常规电泳、转膜、封闭后行Western-blotting显影，显影后使用Image J软件计算相对灰度值。</p></sec><sec id="s4_6"><title>2.6. miR-210-3p靶基因预测与验证</title><p>采用TargetScan 7.2预测miR-210-3p的下游靶基因，然后采用双荧光素酶实验，收集miR-210-3p低表达组与阴性对照组的细胞，加入1&#215;Passive Lysis Buffer，裂解15分钟后向检测管内加入100μL的LAR II (将Luciferase Assay Substrate溶解于Luciferase Assay Buffer II中)，随后上机设置程序；向上述每一个检测管内加入20 μL对应的步骤4中得到的细胞裂解液，并检测萤火虫荧光素酶活性；向每一个检测管中加入100 μL的1&#215;Stop &amp; Glo Reagent，并检测海肾荧光素酶活性。</p></sec><sec id="s4_7"><title>2.7. 统计学方法</title><p>采用SPSS22.0统计软件计量资料用均数 &#177; 标准差(SD)表示，并采用两样本t检验(College Station, TX, USA)进行数据分析，P值&lt;0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 细胞转染情况</title><p>qPCR检测大鼠垂体瘤MMQ与GH3细胞株中的miR-210-3p的表达，其中，低表达病毒组的MMQ细胞系miR-210-3p显著下降(P &lt; 0.05)，GH3细胞系P = 0.0594，较MMQ组稍有差异，NC组与空白组(阴性对照组)对比miR-210-3p的表达无差异(P &gt; 0.05)表面细胞转染成功(见图1)。</p><p>图1. 转染inhibitor后两组垂体瘤细胞株的miR-210-3p的表达情况</p></sec><sec id="s5_2"><title>3.2. 细胞增殖情况</title><p>我们利用CCK-8检测了MMQ与GH3细胞株的增殖情况，低表达miR-210-3p后的MMQ与GH3细胞株细胞增殖能力较阴性对照组下降(P &lt; 0.05)，而NC组与空白对照组(阴性对照组)相比对，增殖情况不存在差异(见图2)。</p><p>图2. 低表达miR-210-3p对MMQ与GH3细胞株的影响，低表达miR-210-3p后，GH3和MMQ细胞株的增殖随着时间延长，逐渐下降</p></sec><sec id="s5_3"><title>3.3. 细胞迁移情况</title><p>我们采用Transwell法检测了MMQ细胞与GH3细胞跨Matrigel胶的移行能力，结果显示，低表达miR-210-3p组的细胞迁移跨胶能力下降(P &lt; 0.05)，但在NC组与空白组中，GH3细胞与MMQ细胞的迁移能力较强，NC组与空白组(阴性对照组)对比无明显差异(见图3)。</p><p>图3. 低表达miR-210-3p后对MMQ和GH3细胞株迁移能力的影响，低表达miR-210-3p的MMQ与GH3细胞株迁移能力下降</p></sec><sec id="s5_4"><title>3.4. 细胞中相关蛋白表达情况</title><p>我们采用Western-blotting检测低表达miR-210-3p后，GH3与MMQ细胞中的靶基因FGFRL-1蛋白表达，结果显示低表达miR-210-3p组的MMQ与GH3细胞中，靶基因FGFRL-1的蛋白表达明显高于NC组与空白组(P &lt; 0.05)，NC组与空白对照组(阴性对照组)对比无明显差异，内参为Tubulin (见图4)。</p><p>图4. 靶基因FGFRL-1的蛋白表达情况</p></sec><sec id="s5_5"><title>3.5. miR-210-3p与FGFRL-1靶点预测与双荧光素酶报告</title><p>我们通过TargetScan7.2在线预测软件发现miR-210-3p与FGFRL-1之间存在靶向结合位点(见图5)。因此，我们通过双荧光素酶报告进行了验证，结果显示pmirGLO/FGFRL-1-UTR+miR-210-mim组中荧光素酶活性明显低于无关序列组(P &lt; 0.05)，结果进一步确定了miR-210-3p的靶基因是FGFRL-1 (见图6)。</p><p>图5. TargetScan7.2软件预测靶基因</p><p>图6. 双荧光素酶报告基因</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>我们知道垂体腺瘤是常见的颅内良性肿瘤，近年来，随着体检的普及与人们对健康的重视，垂体瘤的检出率越来越高，针对垂体瘤的治疗，我们现在还是手术为主，但是该疾病的复发和周围侵袭是影响垂体瘤治疗的一大关键因素。这提示我们是否可以从分子生物学角度来考虑疾病的诊疗，目前对于miRNA是否参与垂体瘤发生发展的的作用机制较少 [<xref ref-type="bibr" rid="hanspub.36441-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.36441-ref14">14</xref>]，而miR-210-3p是否参与垂体瘤腺瘤的发病和进展我们尚且未见相关文献报道。此次我们在大鼠垂体瘤MMQ与GH3细胞系中先进行了初步探索，发现了miR-210-3p与MMQ与GH#垂体瘤细胞的增殖与迁移有一定相关性，我们知道，垂体腺瘤的发展过程中，垂体腺瘤细胞数目和迁移能力均可影响到垂体瘤的进展，通俗来讲，数目越多，垂体瘤越大，迁移能力越强，越容易向周围组织侵袭。所以，一定程度上我们可以说垂体瘤细胞的增殖活力，可反映垂体瘤的复发程度。本研究发现，低表达miR-210-3p可抑制大鼠MMQ与GH3垂体瘤细胞的增殖和迁移，提示miR-210-3p可能通过干预垂体瘤细胞的增殖从而参与垂体瘤的形成过程。</p><p>关于miRNA我们知道它的主要作用途径是通过作用于靶蛋白mRNA抑制靶基因RNA转录后的基因表达，从而来影响对应靶蛋白及相关的信号通路 [<xref ref-type="bibr" rid="hanspub.36441-ref15">15</xref>]。Amaral等 [<xref ref-type="bibr" rid="hanspub.36441-ref16">16</xref>] 发现，多种microRNA可以通过调节靶基因表达水平，从而参与ACTH分泌型垂体腺瘤发病过程。本研究结果显示，低表达miR-210-3p后，MMQ与GH3细胞中FGFRL-1的表达增加，而FGFRL-1在相关研究 [<xref ref-type="bibr" rid="hanspub.36441-ref9">9</xref>] 中发现FGFRL-1是一种单通道I型膜蛋白，属于FGF受体家族，成熟的FGFRL-1由354个氨基酸胞外结构、3个类似IgG的c2型结构域、21个氨基酸跨膜段和134个氨基酸胞质结构组成。调节大多数细胞类型的生长、凋亡、分化和迁移，细胞中FGFRL-1的表达量与细胞增殖能力呈反比 [<xref ref-type="bibr" rid="hanspub.36441-ref10">10</xref>]。本研究结果提示miR-210-3p在MMQ与GH3垂体瘤细胞系中，能通过调节靶基因FGFRL-1的表达来影响垂体瘤细胞的增殖与迁移，参与垂体瘤细胞的病理生理过程。在预测软件TargetScan7.2中我们发现了miR-210-3p的靶基因是FGFRL-1，相关研究表明FGFRL-1参与了多种肿瘤的发生以及发展 [<xref ref-type="bibr" rid="hanspub.36441-ref10">10</xref>]。我们知道侵袭性垂体瘤是神经外科非常棘手的问题，因为肿瘤侵袭性生长使得外科手术无法全切除，导致肿瘤复发。尽管肿瘤发生和发展的机制尚不清楚，但肿瘤部分生物学特性已经阐明，一些基因表达改变在肿瘤发生中起重要作用。一些基因表达改变与垂体腺瘤侵袭性相关，如成纤维生长因子(fibroblast growth factors, FGF)和成纤维生长因子受体(fibroblast growth factorreceptors, FGFR)基因表达水平改变与垂体腺瘤侵袭性相关。与非侵袭性垂体腺瘤相比，FGF基因在侵袭性垂体腺瘤表达上调 [<xref ref-type="bibr" rid="hanspub.36441-ref1">1</xref>]。在垂体瘤细胞中，FGFR基因过表达可诱导细胞侵袭性生长 [<xref ref-type="bibr" rid="hanspub.36441-ref18">18</xref>]。本研究采用了双荧光素酶报告实验进一步证实了FGFRL-1是miR-210-3p的靶基因，miR-210-3p可调节FGFRL-1且miR-210-3p在GH3和MMQ细胞中的表达水平与FGFRL-1呈反比。</p><p>本研究的通过低表达GH3与MMQ大鼠垂体瘤细胞中的miR-210-3p，研究其对MMQ和GH3细胞生物学行为的影响，结果证实，低表达miR-210-3p能够抑制大鼠MMQ和GH3垂体瘤细胞的增殖与迁移，但是本实验未在人体组织和人体垂体瘤组织中验证，只是初步在动物肿瘤细胞模型上进行了初步研究，后续会在垂体瘤肿瘤组织层面进行相关研究与实验。初步我们得出的结论是低表达miR-210-3p抑制了大鼠垂体瘤MMQ和GH3细胞的增殖与迁移，miR-210-3p可能成为治疗垂体瘤的一个潜在靶点。</p></sec><sec id="s7"><title>基金项目</title><p>国家自然科学基金青年项目(81602182)。</p></sec><sec id="s8"><title>致谢</title><p>感谢姚维成主任在文章撰写过程的指导，感谢王建鹏主任的国家自然科学基金青年项目(81602182，miR-340通过Notch信号通路介导GSCs的“干性”抑制)以及同门谭维康的实验帮助和蒋亚楠的作图帮助。</p></sec><sec id="s9"><title>文章引用</title><p>王成浩,谭维康,蒋亚楠,王建鹏,姚维成. 低表达miR-210-3p调控大鼠垂体瘤GH3与MMQ细胞株增殖与迁移The Low Expression of miR-210-3p Regulates the Proliferation and Migration of GH3 and MMQ Cell Lines in Rat Pituitary Adenoma[J]. 临床医学进展, 2020, 10(07): 1260-1268. https://doi.org/10.12677/ACM.2020.107192</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36441-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">王忠诚. 王忠诚神经外科学[M]. 武汉: 湖北科学技术出版社, 2005: 620.</mixed-citation></ref><ref id="hanspub.36441-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rey, J.A., Bello, M.J., de Campos, J.M., et al. (1986) A Case of Pituitary Adenoma with 58 Chromosomes. Cancer Genetics and Cytogenetics, 23, 171-174. &lt;br&gt;https://doi.org/10.1016/0165-4608(86)90415-2</mixed-citation></ref><ref id="hanspub.36441-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Roelfsema, F., Biermasz, N.R. and Pereira, A.M. (2012) Clinical Factors Involved in the Recurrence of Pituitary Adenomas after Surgical Remission: A Structured Review and Meta-Analysis. Pituitary, 15, 71-83.  
&lt;br&gt;https://doi.org/10.1007/s11102-011-0347-7</mixed-citation></ref><ref id="hanspub.36441-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Day, P.F., Loto, M.G., Glerean, M., et al. (2016) Incidence and Prevalence of Clinically Relevant Pituitary Adenomas: Retrospective Cohort Study in a Health Management Organization in Buenos Aires, Argentina.</mixed-citation></ref><ref id="hanspub.36441-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W. (2011) Progress on Hypoxic Regulatory Factor miR-210. Chinese Journal of Pathophysiology, 27, 813.</mixed-citation></ref><ref id="hanspub.36441-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">杨巍. 乏氧调控因子miR-210的研究进展[J]. 中国病理生理杂志, 2011, 27(4): 813.</mixed-citation></ref><ref id="hanspub.36441-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Giannakakis, A., Sandaltzopoulos, R., Greshock, J., et al. (2007) miR-210 Links Hypoxia with Cell Cycle Regulation and Is Deleted in Human Epithelial Ovarian Cancer. Cancer Biology &amp; Therapy, 7, 255.  
&lt;br&gt;https://doi.org/10.4161/cbt.7.2.5297</mixed-citation></ref><ref id="hanspub.36441-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Fasanaro, P., Alesandra, Y., Stefano, V., et al. (2008) MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3. Journal of Biological Chemistry, 283, 15878- 15883. &lt;br&gt;https://doi.org/10.1074/jbc.M800731200</mixed-citation></ref><ref id="hanspub.36441-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gee, H.E., Camps, C., Buffa, F.M., Patiar, S., Winter, S.C., Betts, G., Homer, J., Corbridge, R., Cox, G., West, C.M., Ragoussis, J. and Harris, A.L. (2010) hsa-mir-210 Is a Marker of Tumor Hypoxia and a Prognostic Factor in Head and Neck Cancer. Cancer, 116, 2148-2158. &lt;br&gt;https://doi.org/10.1002/cncr.25009</mixed-citation></ref><ref id="hanspub.36441-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ho, A.S., Huang, X., Cao, H., Christman-Skieller, C., Bennewith, K., Le, Q.T. and Koong, A.C. (2010) Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Translational Oncology, 3, 109-113.  
&lt;br&gt;https://doi.org/10.1593/tlo.09256</mixed-citation></ref><ref id="hanspub.36441-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">di Martino, E., Taylor, C.F., Roulson, J.A. and Knowles, M.A. (2013) An Integrated Genomic, Transcriptional and Protein Investigation of FGFRL1 as a Putative 4p16.3 Deletion Target in Bladder Cancer. Genes Chromosomes Cancer, 52, 860-871. &lt;br&gt;https://doi.org/10.1002/gcc.22082</mixed-citation></ref><ref id="hanspub.36441-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schild, C. and Trueb, B. (2005) Aberrant Expression of FGFRL1, a Novel FGF Receptor, in Ovarian Tumors. International Journal of Molecular Medicine, 16, 1169-1173. &lt;br&gt;https://doi.org/10.3892/ijmm.16.6.1169</mixed-citation></ref><ref id="hanspub.36441-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">徐川, 张怀壁, 康继辉, 等. miRNA在PRL型垂体瘤患者血清中的表达[J]. 世界中西医结合杂志, 2015(4): 543-548.</mixed-citation></ref><ref id="hanspub.36441-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Palumbo, T., Faucz, F.R., Azevedo, M., et al. (2013) Functional Screen Analysis Reveals miR-26b and miR-128 as Central Regulators of Pituitary Somatomammotrophic Tumor Growth through Activation of PTEN-AKT Pathway. Oncogene, 32, 1651-6459. &lt;br&gt;https://doi.org/10.1038/onc.2012.190</mixed-citation></ref><ref id="hanspub.36441-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Tsuchiya, S., Fujiwara, T., Sato, F., Shimada, Y., Tanaka, E., Sakai, Y., Shimizu, K. and Tsujimoto, G. (2011) MicroRNA-210 Regulates Cancer Cell Proliferation through Targeting Fibroblast Growth Factor Receptor-Like 1 (FGFRL1). Journal of Biological Chemistry, 286, 420-428. &lt;br&gt;https://doi.org/10.1074/jbc.M110.170852</mixed-citation></ref><ref id="hanspub.36441-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Amaral, F.C., Torres, N., Saggioro, F., et al. (2009) MicroRNAs Differentially Expressed in ACTH-Secreting Pituitary Tumors. The Journal of Clinical Endocrinology &amp; Metabolism, 94, 320-323. &lt;br&gt;https://doi.org/10.1210/jc.2008-1451</mixed-citation></ref><ref id="hanspub.36441-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Li, S., Yang, J., Wang, J., et al. (2018) Down-Regulation of miR-210-3p Encourages Chemotherapy Resistance of Renal Cell Carcinoma via Modulating ABCC1. Cell &amp; Bioscience, 8, 9. &lt;br&gt;https://doi.org/10.1186/s13578-018-0209-3</mixed-citation></ref><ref id="hanspub.36441-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Morita, K., Takano, K., Yasufuku-Takano, J., et al. (2008) Expression of Pituitary Tumour-Derived, N-Terminally Truncated Isoform of Fibroblast Growth Factor Receptor 4 (ptd-FGFR4) Correlates with Tumour Invasiveness But Not with G-Protein Alpha Subunit (Gsp) Mutation in Human GH-Secreting Pituitary Adenomas. Clinical Endocrinology, 68, 435-441.</mixed-citation></ref></ref-list></back></article>